S.B.L. Ltd. v. Himalaya Drug Company — "Liv.52" v. "Liv-T" Trademark Case

Citation & Court

S.B.L. Ltd. v. Himalaya Drug Company, Delhi High Court, proceedings in 1997 and 2010, concerning the marks "LIV.52" and "LIV-T."

The Dispute

Himalaya Drug Company had used the coined mark "Liv.52" continuously since 1955 (registered since 1957) for a liver-treatment formulation. S.B.L. Ltd. began marketing a similar product under "LIV-T." Himalaya alleged that "LIV" — the dominant, distinctive element of its mark — was being copied.

What the Court Held

The Delhi High Court held that "LIV" was the essential and distinctive feature of Himalaya's "Liv.52" mark, not a medically generic term, and restrained S.B.L. from using "LIV" in isolation as part of its own mark for a competing liver medicine. The Court found close visual and phonetic similarity between "LIV.52" and "LIV-T" and held that, once that similarity is established for medicinal products, the plaintiff need not separately prove actual instances of consumer deception — the finding of infringement follows.

How to Use This in Your Reply

Useful whenever a dispute turns on which part of a compound or abbreviated mark is its "essential feature" — the analysis here shows how a court isolates the dominant, source-identifying element (here, "LIV") from a merely descriptive or numeric suffix. It's also a good citation on the point that for pharmaceutical marks, close similarity alone can be enough without separate proof of actual confusion.

Key takeaway: For compound marks, protection typically centres on the dominant, distinctive component — and for medicinal products, similarity itself can suffice without extra proof of real-world confusion.